Torecan

Selected form

Thiethylperazine

Method of action: Antiemetic

Treatment option: Lightheadedness,Dizzy, Sea Sickness, Burping, Morning Sickness

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Torecan

Quick Facts

Property	Description
Active ingredient	Thiethylperazine (usually as Maleate salt)
Form	Tablets, Injectable Solution, Suppositories
Pharmacological class	Antiemetic, Phenothiazine Derivative
Common use	Suppression of Nausea and Vomiting
Origin	Synthetic

What Type of Medicine is Torecan and What Class Does it Belong To?

Torecan is a trade name for the prescription medicine containing the active substance Thiethylperazine, which is typically prepared as the Maleate salt. This compound is clinically recognized as a potent antiemetic agent. Thiethylperazine is chemically identified as a phenothiazine derivative, distinguishing it structurally from newer classes of anti-sickness medications. As a single-ingredient pharmaceutical, its functional identity is confirmed by its specific therapeutic role in countering acute nausea and vomiting.

Forms and Primary Purpose of the Active Ingredient

The active substance, Thiethylperazine, is prepared in multiple pharmaceutical forms to suit variable clinical needs and allows flexible routes of administration. These preparations include oral tablets, a fast-acting injectable solution for deep intramuscular delivery, and suppositories for rectal use. The provision of these different forms ensures that the medicine can be reliably administered even during episodes where oral intake is compromised. The fundamental purpose of this compound is the specific and efficient suppression of the body’s emetic reflex.

How Does Thiethylperazine Counter Nausea? (Mechanism Concept)

The effective antiemetic action of Thiethylperazine is rooted in its highly specific function as a Dopamine D2 receptor antagonist. This mechanism involves the direct, central blockage of D2 receptors found within the brain’s Chemoreceptor Trigger Zone (CTZ). The CTZ acts as the body's primary detector for emetic stimuli. By targeting and blocking the receptors in this zone, Thiethylperazine prevents the transmission of signals that initiate the vomiting reflex, providing a direct, centralized method for inhibiting the reflex that causes symptoms of nausea and vomiting.

What side effects are possible with Torecan?

Possible Side Effects and Safety Information

The safety profile of thiethylperazine, a phenothiazine derivative, is defined by adverse reactions classified according to their frequency and the physiological systems affected, as documented in official government regulatory labels.

Documented Adverse Reactions and Frequencies

Adverse reactions are organized by System-Organ Class (SOC) in regulatory safety documentation. Effects involving the Nervous System are prominent, where sedation, drowsiness, and dizziness are generally classified as common occurrences. Other systems affected include the Vascular System, which may include orthostatic hypotension (low blood pressure upon standing) classified as uncommon, and Gastrointestinal Disorders such as dry mouth and constipation.

Serious Safety Considerations

The official labeling highlights several serious adverse reactions associated with the phenothiazine class. These include Extrapyramidal Symptoms (EPS), a group of involuntary movement disorders such as acute dystonia and tremor. The risk of developing certain acute EPS is often related to the start of treatment or dose escalation. For individuals on long-term treatment, there is a documented risk of developing Tardive Dyskinesia (TD), a potentially irreversible movement syndrome. Additionally, the label addresses the risk of Neuroleptic Malignant Syndrome (NMS), a rare but life-threatening condition.

Population-Specific Safety Notes

The regulatory safety profile includes specific constraints for certain groups. Older adults may exhibit increased sensitivity to the medicine, potentially increasing the risk for effects like sedation and hypotension. Caution and specific safety monitoring constraints are also advised for individuals with severe hepatic or renal impairment. The medicine is formally contraindicated in patients with severe central nervous system depression or coma.

Overdose and Emergency Response

Torecan Overdose and when to seek help

Acute overdosage of thiethylperazine, the active ingredient in Torecan, is expected to reflect severe Central Nervous System (CNS) effects. Immediate medical attention is required for any suspected overdosage situation.

Documented Manifestations

System Affected	Officially Documented Symptoms/Signs
Neurological/CNS	Overdose presentations include neurological signs such as Extrapyramidal Symptoms (E.P.S.), which may manifest as muscle spasms of the face or neck. Further signs include confusion, convulsions (seizures), and a reduction or absence of reflexes.
Cardiopulmonary	The serious and life-threatening outcomes documented in regulatory sources are respiratory depression and severe hypotension (low blood pressure), indicating cardiopulmonary depression.

Emergency Action and Management

If overdosage is suspected, the official guidance strictly mandates that you contact a local poison control center or emergency room immediately. The definitive management approach for overdosage is symptomatic and supportive, focusing on maintaining all vital functions, including securing an open airway and optimizing breathing and circulation. No specific pharmacological antidote is identified in the official prescribing information. Regulatory documents note that elderly patients are generally more sensitive to the effects of phenothiazine medicines and may be more susceptible to overdosage manifestations.

Therapeutic Uses of Torecan

What Torecan Treats: Main Uses and Benefits

Torecan, which contains the active ingredient thiethylperazine, is considered relevant for easing symptoms related to physical discomfort such as nausea and vomiting. It is applied across domains where additional symptomatic support is needed for the relief of these symptoms that interfere with daily functioning.

This medicine may assist with managing nausea and vomiting associated with a variety of causes. These therapeutic areas often involve conditions marked by increased physiological stress, such as those related to anesthesia, radiation therapy, certain medical treatments (like chemotherapy agents), or exposure to toxins. The use of Torecan is generally applied in scenarios where additional management of discomfort is required, and its primary role is to provide support that helps ease the overall symptom burden.

The medication provides support that contributes to improved day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Nausea and Vomiting

Eligibility and Restrictions for Use

Who Can and Cannot Use Torecan?

The population eligibility for Torecan (thiethylperazine) is strictly defined by regulatory documents based on contraindications, age, reproductive status, and pre-existing conditions.

Contraindications and Absolute Restrictions

Use is contraindicated (absolutely prohibited) for patients with a known hypersensitivity to any medicine in the phenothiazine class. Torecan is also contraindicated in pregnancy. Administration by the intravenous route is prohibited due to the risk of severe hypotension. The medicine must not be used in patients with severe CNS depression or comatose states.

Population-Specific Limitations

Patient Group	Regulatory Status
Pediatric Patients	Safety and effectiveness have not been established.
Older Adults (Geriatric)	Usually more sensitive to effects; requires specific precautions.
Lactating Patients	Not recommended; nursing should generally not be undertaken while on the drug.
Renal/Hepatic Impairment	Usual precautions should be observed due to potential changes in drug clearance.

Use requires caution in patients with conditions like seizure disorders, Parkinson's disease, glaucoma, or cardiovascular disease, as outlined in official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information documents interactions classified primarily as Pharmacodynamic Potentiation and Pharmacokinetic Interference.

Interaction Scope

Co-administration with Central Nervous System (CNS) Depressants may result in additive depressant effects. This category includes specific substances such as opiates, sedatives, antihistamines, and Alcohol (Ethanol). Furthermore, the official label mandates a critical procedural restriction: epinephrine must be avoided in the treatment of drug-induced hypotension, as phenothiazines can induce a reversed pressor effect.

Pharmacokinetic and Population Notes

A separate class of interactions involves Pharmacokinetic Interference. Regulatory data notes that certain antacids (specifically those containing Aluminum or Magnesium) can interfere with the drug's uptake, leading to decreased absorption and a reduced serum concentration of thiethylperazine. Conversely, this medication may decrease the excretion rate of other co-administered drugs, resulting in an officially noted increase in their serum concentration. Population-specific considerations are also documented, requiring precautions for patients with impaired hepatic function due to the officially noted risk of drug accumulation.

Connection to the overall interaction profile

The documented interaction structure focuses on two primary areas: additive depressant effects with other CNS-active agents, and specific drug avoidance mandates based on the potential for paradoxical cardiovascular outcomes. The regulatory documentation defines the product’s interaction profile through clear statements on potentiation, reduced absorption, and altered clearance, strictly limiting interpretation to these functional outcomes.

Mechanism of Action

The action of Torecan (thiethylperazine) is defined by its targeted engagement with central and peripheral pathways, resulting in the modulation of overactive signaling.

Blocking Signals in the Chemoreceptor Trigger Zone (CTZ)

Torecan primarily functions as an antagonist of dopamine D2 receptors, focusing its action on the Chemoreceptor Trigger Zone (CTZ) in the brain. This mechanism suppresses the signaling sequence within the CTZ, which is sensitive to various chemical and humoral stimuli that engage the emetic pathway. This action modulates excessive mediator activity, contributing to the adjustment of overactive physiological responses within the targeted pathway.

Modulating Multiple Neuroreceptor Pathways

Beyond D2 antagonism, the drug engages secondary mechanisms by acting as a low-affinity antagonist at other receptors, including histamine H1 and muscarinic cholinergic receptors. This multi-receptor profile modulates additional pathways associated with heightened physiological responses, such as those originating from the vestibular sensory organ. This activity influences downstream effects and facilitates the adjustment of signaling activity within the targeted pathways.

Dosage and Administration Information

How Torecan is Used: Administration Guidelines

The instructions for using Torecan (thiethylperazine) define a structured protocol encompassing routes, specific dosing, and procedural conditions.

Administration Feature	Guideline
Approved Routes	Oral (Tablets), Deep Intramuscular (IM) Injection, and Rectal (Suppositories)
Standard Dose & Max	10 mg per dose; Maximum total daily dose is 30 mg.
Frequency Pattern	Administered on an as-needed basis, typically up to three times per day

The standard regimen specifies a dose of 10 mg for adults and pediatric patients aged 12 and older. This dosage regimen of 10 mg, up to three times daily, defines the frequency pattern for short-term use.

Administration also requires adherence to specific procedural conditions. Oral tablets are instructed to be taken with food or a full glass of water or milk to help reduce potential gastrointestinal upset. When the injectable form is used, it must be delivered via a deep IM injection into a large muscle mass. Crucially, a specific post-injection condition requires the patient to remain at rest for a minimum of one hour immediately following the intramuscular administration. Furthermore, a standard dosage for pediatric patients under 12 years of age is not established, requiring individual determination by a health professional.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Thiethylperazine (Torecan)

Research Evidence for Nausea and Vomiting Related to Cancer Treatment

This section will summarize the types of Randomized Controlled Trials (RCTs) and comparative studies that have examined thiethylperazine’s application in research exploring how symptoms change over time associated with chemotherapy and radiation therapy. The focus will be on the study designs used in research exploring how symptoms change over time, the specific outcomes related to physical discomfort that were measured, and the patient populations that were included in this body of research.

For symptoms related to cancer chemotherapy, research has explored short-term symptom changes in adult patients receiving various regimens. Studies monitored outcomes describing episodic or acute changes such as the frequency of vomiting episodes and the patient-reported severity of nausea. Findings describe patterns observed in the studies regarding outcomes related to episodic or acute changes shortly after receiving medication. However, certain comparative evidence is lacking when placing these older findings against antiemetic agents developed more recently, and its current place in the broader evidence landscape is one of the aspects that was evaluated in these comparisons.

Research Evidence for Post-Operative Nausea and Vomiting (PONV)

This section will outline the structure of the evidence base concerning the use of thiethylperazine immediately following surgical procedures. It will describe the historical context of clinical trials and the short-term outcomes related to systemic or functional imbalance that were prioritized for measurement in these post-operative settings.

Research examined its application in conditions associated with acute or disruptive episodes, such as those immediately following general anesthesia. The study outcomes examined included the incidence and frequency of nausea and vomiting during the immediate post-operative period, which are outcomes reflecting daily functioning or activity level. Studies reported how symptoms evolved in the observed populations, and findings indicate patterns related to the need for additional anti-sickness treatments in the recovery room.

Evidence Structure for Vomiting of Early Pregnancy

This part of the overview will describe the nature of the research available for this specific application, including the reliance on older clinical reports and epidemiological (observational) studies. It will clarify the difference between intervention trials and studies focused on tracking general outcomes over time.

Thiethylperazine was studied for managing symptoms in conditions where symptoms may vary in intensity, specifically the vomiting of early pregnancy. Research explored short-term symptom changes, and older clinical reports described patterns observed in the studies regarding the reported severity of early pregnancy sickness. The evidence is limited for this application, primarily reflecting the primary reliance on older trials and observational study designs. Specific regulatory characteristics apply to the evidence for this population.

Key Uncertainties and Research Gaps in the Evidence

This final summary will synthesize the areas where the research evidence is noted as being limited or incomplete, including reliance on older trial designs, small sample sizes, or inconsistent findings across comparative trials. It will focus on documenting what is still uncertain.

A key gap is the historical nature of much of the primary evidence; many core studies were conducted decades ago, and the direct relevance of these older findings to current practice is less certain. Comparative evidence is lacking for many direct, head-to-head comparisons against newer, standard-of-care antiemetic classes in large-scale modern RCTs. Furthermore, follow-up durations were limited across the core indications. Evidence suggests that long-term effects are not fully established.

Key Studies & References

How should Torecan be stored and disposed of?

How to Store and Dispose of Torecan (Thiethylperazine)

The storage and disposal of Torecan must strictly follow official regulatory requirements to maintain product stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store both tablets and injection below 86°F (30°C).
Protection	Keep away from heat and excessive moisture; protect the injection from light and keep from freezing.
Container	Tablets must be kept in a tight, light-resistant container.
Stability Check	The injection should be used only if clear and colorless; discard if discolored or if particulate matter is present.
Safety	Must be stored out of the reach of children.

Disposal Instructions

Expired or unused Torecan should be disposed of through a drug take-back program. If a program is unavailable, mix the medicine with an undesirable substance (e.g., dirt) and place it in a sealed container for household trash. Do not flush Torecan down the toilet, and always scratch out personal information from the label before discarding the packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.